CY1115404T1 - Παραγωγα θειενο-πυριδινης ως αναστολεις μεκ - Google Patents
Παραγωγα θειενο-πυριδινης ως αναστολεις μεκInfo
- Publication number
- CY1115404T1 CY1115404T1 CY20141100415T CY141100415T CY1115404T1 CY 1115404 T1 CY1115404 T1 CY 1115404T1 CY 20141100415 T CY20141100415 T CY 20141100415T CY 141100415 T CY141100415 T CY 141100415T CY 1115404 T1 CY1115404 T1 CY 1115404T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mek
- antolosis
- thieno
- pyridines
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Μια σειρά παραγώγων θειενο[2,3-b]πυριδίνης που είναι υποκατεστημένα στη θέση 2 από ένα υποκατεστημένο τμήμα ανιλίνης, που είναι επιλεκτικοί αναστολείς ανθρώπινων ενζύμων ΜΕΚ (ΜΑΡΚΚ), είναι συνεπώς ωφέλιμα για την ιατρική, για παράδειγμα στην αντιμετώπιση φλεγμονωδών, αυτοάνοσων, καρδιαγγειακών, πολλαπλασιαστικών (συμπεριλαμβανομένων των ογκολογικών) και αλγαισθητικών καταστάσεων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0601962.4A GB0601962D0 (en) | 2006-01-31 | 2006-01-31 | Therapeutic agents |
EP07705076.3A EP1981892B1 (en) | 2006-01-31 | 2007-01-30 | Thieno-pyridine derivatives as mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115404T1 true CY1115404T1 (el) | 2017-01-04 |
Family
ID=36100789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100415T CY1115404T1 (el) | 2006-01-31 | 2014-06-11 | Παραγωγα θειενο-πυριδινης ως αναστολεις μεκ |
Country Status (27)
Country | Link |
---|---|
US (3) | US8283359B2 (el) |
EP (1) | EP1981892B1 (el) |
JP (1) | JP5249787B2 (el) |
KR (1) | KR101446919B1 (el) |
CN (1) | CN101379067B (el) |
AU (1) | AU2007211377B2 (el) |
BR (1) | BRPI0708016B1 (el) |
CA (1) | CA2640594C (el) |
CY (1) | CY1115404T1 (el) |
DK (1) | DK1981892T3 (el) |
EA (1) | EA016128B1 (el) |
EC (1) | ECSP088704A (el) |
ES (1) | ES2471970T3 (el) |
GB (1) | GB0601962D0 (el) |
HK (1) | HK1125924A1 (el) |
HR (1) | HRP20140503T1 (el) |
IL (1) | IL192603A (el) |
MY (1) | MY146387A (el) |
NO (1) | NO341064B1 (el) |
NZ (1) | NZ569638A (el) |
PL (1) | PL1981892T3 (el) |
PT (1) | PT1981892E (el) |
RS (1) | RS53342B (el) |
SI (1) | SI1981892T1 (el) |
UA (1) | UA95939C2 (el) |
WO (1) | WO2007088345A1 (el) |
ZA (1) | ZA200807447B (el) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
CA2708176A1 (en) * | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines and methods of use |
WO2009093008A1 (en) * | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) * | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
JP5503930B2 (ja) * | 2009-09-18 | 2014-05-28 | 住友化学株式会社 | 3−アミノ−1−tert−ブトキシカルボニルピペリジンの精製方法およびそのクエン酸塩 |
EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
ES2798899T3 (es) | 2013-02-25 | 2020-12-14 | Novartis Ag | Mutación novedosa del receptor de andrógenos |
EA201690089A1 (ru) | 2013-06-11 | 2017-04-28 | Латвийский Институт Органического Синтеза | ТИЕНО[2,3-b]ПИРИДИНЫ КАК МОДУЛЯТОРЫ СОСТОЯНИЯ МНОЖЕСТВЕННОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТИ |
EP3632208A1 (en) | 2013-06-13 | 2020-04-08 | Biomatrica, INC. | Cell stabilization |
US10064404B2 (en) | 2014-06-10 | 2018-09-04 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
ES2946184T3 (es) | 2015-12-08 | 2023-07-13 | Biomatrica Inc | Reducción de la velocidad de eritrosedimentación |
EP3624796A1 (en) * | 2017-05-19 | 2020-03-25 | NFlection Therapeutics, Inc. | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
MX2019013562A (es) | 2017-05-19 | 2020-08-03 | Nflection Therapeutics Inc | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. |
CN109836434B (zh) * | 2017-11-27 | 2020-09-25 | 上海宇耀生物科技有限公司 | 噻吩并环类化合物及其合成方法和应用 |
CA3120351A1 (en) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers |
WO2020106306A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
CN111138449B (zh) * | 2020-01-15 | 2022-11-29 | 四川大学华西医院 | 双靶向erk1和erk5抑制剂的制备及其抗肿瘤应用 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE344791T1 (de) | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
EP1150950A2 (en) | 1999-01-13 | 2001-11-07 | Warner-Lambert Company | Anthranilic acid derivatives |
OA11746A (en) | 1999-01-13 | 2005-05-13 | Warner Lambert Co | Benzoheterocycles and their use as MEK inhibitors. |
DK1301472T3 (da) | 2000-07-19 | 2014-04-07 | Warner Lambert Co | Oxygenerede estere af 4-iod-phenylamino-benzhydroxamsyrer |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
AU2003220202A1 (en) | 2002-03-13 | 2003-09-29 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
KR100984613B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체 |
US20030225273A1 (en) | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
JP2006512338A (ja) * | 2002-12-12 | 2006-04-13 | ファルマシア・コーポレーション | マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−2阻害剤としてのアミノシアノピリジンの使用法 |
AU2004249495A1 (en) | 2003-06-20 | 2004-12-29 | Ucb Pharma S.A. | Thienopyridone derivatives as kinase inhibitors |
AU2004249498B2 (en) * | 2003-06-20 | 2009-11-19 | Ucb Pharma S.A. | Thienopyridone derivatives as kinase inhibitors |
US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
DE602004023207D1 (de) | 2003-07-24 | 2009-10-29 | Warner Lambert Co | Benzimidazol-derivate als mek-hemmer |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AU2004270394A1 (en) * | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
EP1689387B1 (en) | 2003-11-19 | 2011-09-14 | Array Biopharma, Inc. | Bicyclic inhibitors of mek and methods of synthesis thereof |
US7217723B2 (en) | 2004-02-02 | 2007-05-15 | Eisai Co., Ltd. | Heterocyclic compound having oxime group |
WO2007027855A2 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
BRPI0617165B1 (pt) | 2005-10-07 | 2023-10-03 | Exelixis Inc | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
EP2056829B9 (en) | 2006-08-16 | 2012-09-26 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
-
2006
- 2006-01-31 GB GBGB0601962.4A patent/GB0601962D0/en not_active Ceased
-
2007
- 2007-01-30 BR BRPI0708016-6A patent/BRPI0708016B1/pt active IP Right Grant
- 2007-01-30 UA UAA200809945A patent/UA95939C2/ru unknown
- 2007-01-30 JP JP2008552878A patent/JP5249787B2/ja active Active
- 2007-01-30 KR KR1020087018972A patent/KR101446919B1/ko active IP Right Grant
- 2007-01-30 CN CN2007800040774A patent/CN101379067B/zh active Active
- 2007-01-30 PT PT77050763T patent/PT1981892E/pt unknown
- 2007-01-30 CA CA2640594A patent/CA2640594C/en active Active
- 2007-01-30 WO PCT/GB2007/000310 patent/WO2007088345A1/en active Application Filing
- 2007-01-30 DK DK07705076.3T patent/DK1981892T3/da active
- 2007-01-30 RS RS20140304A patent/RS53342B/en unknown
- 2007-01-30 EA EA200801684A patent/EA016128B1/ru not_active IP Right Cessation
- 2007-01-30 MY MYPI20082765A patent/MY146387A/en unknown
- 2007-01-30 ES ES07705076.3T patent/ES2471970T3/es active Active
- 2007-01-30 ZA ZA200807447A patent/ZA200807447B/xx unknown
- 2007-01-30 EP EP07705076.3A patent/EP1981892B1/en active Active
- 2007-01-30 PL PL07705076T patent/PL1981892T3/pl unknown
- 2007-01-30 NZ NZ569638A patent/NZ569638A/en unknown
- 2007-01-30 AU AU2007211377A patent/AU2007211377B2/en active Active
- 2007-01-30 SI SI200731467T patent/SI1981892T1/sl unknown
-
2008
- 2008-07-03 IL IL192603A patent/IL192603A/en active IP Right Grant
- 2008-07-30 US US12/182,931 patent/US8283359B2/en active Active
- 2008-08-28 EC EC2008008704A patent/ECSP088704A/es unknown
- 2008-08-29 NO NO20083739A patent/NO341064B1/no unknown
-
2009
- 2009-04-20 HK HK09103590.9A patent/HK1125924A1/xx unknown
-
2012
- 2012-09-05 US US13/604,282 patent/US8394822B2/en active Active
-
2013
- 2013-02-06 US US13/760,788 patent/US8604051B2/en active Active
-
2014
- 2014-06-02 HR HRP20140503TT patent/HRP20140503T1/hr unknown
- 2014-06-11 CY CY20141100415T patent/CY1115404T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115404T1 (el) | Παραγωγα θειενο-πυριδινης ως αναστολεις μεκ | |
CY1116734T1 (el) | Παραγωγα κινολινης και κινοξαλινης ως αναστολεις της κινασης | |
CY1120304T1 (el) | Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας | |
CY1117934T1 (el) | Αντιβακτηριακες φαρμακευτικες συνθεσεις | |
DK1768657T3 (da) | Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater | |
ECSP099710A (es) | Derivados de piridina | |
WO2008020206A3 (en) | Fused thiophene derivatives as mek inhibitors | |
CL2011002739A1 (es) | Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras. | |
DK2183937T3 (da) | Fremgangsmåder, apparater og computerprogramprodukt til inter-system overdragelse | |
BRPI0817265A2 (pt) | Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada | |
CR10733A (es) | Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof | |
HK1136557A1 (el) | ||
DK2229391T3 (da) | Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse | |
DK2303872T3 (da) | Isoxazolderivater og deres anvendelse som metabotrope glutamatreceptorforstærkere | |
DK2024372T3 (da) | Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor | |
DK2013208T3 (da) | Pyridin[3,4-B]pyrazinoner | |
MX2009004883A (es) | Piridil sulfoximinas multi-substituidas y su uso como insecticidas. | |
DK2262803T3 (da) | Polysubstituerede derivater af 2-aryl-6-phenyl-imidazo(1,2-A)pyridiner, fremstilling og terapeutisk anvendelse heraf | |
DK2046715T3 (da) | Substituerede 1,3-diphenylpropanderivater, præparater og anvendelser deraf | |
BRPI0812865A2 (pt) | Derivados de 6-anilinopurina substituída como inibidores de citoquinina oxidase/desidrogenase e preparações contendo esses derivados. | |
BRPI0919331A2 (pt) | derivados de pirazolo piridina, composições farmacêuticas e métodos associados | |
DK2124944T3 (da) | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer | |
BRPI1014459A2 (pt) | derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina" | |
MX2009008425A (es) | Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. | |
WO2008013966A3 (en) | Use of 8-quinolinol and its analogs to target cancer stem cells |